NEOPHARM (NEOL) Presents Data From Phase I Study of CINTREDEKIN BESUDOTOX
More News related to NEOL
- NeoPharm, Inc. Provides ARS Update
- NeoPharm (NEOL) Requests Hearing for Continued Listing on NASDAQ
- NeoPharm (NEOL) Begins Enrollment for Phase II Trial of Liposomal Paclitaxel
- NeoPharm (NEOL) Reports a Q4 Loss, Sees Operations Funded Through 2009
- NEOPHARM, Inc. (NEOL) Tops Q2 EPS by 6c
More News related to FDA
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
- Lilly (LLY) Receives Fourth FDA Approval for ALIMTA
- Protalix (PLX) Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD
- ATS Medical (ATSI) Announces FDA Clearance of New ATS Simulus Semi-Rigid Annuloplasty Band
NEOPHARM, Inc. (Nasdaq: NEOL) announced the presentation of final Phase 1 safety results at the Society for Neuro-Oncology (SNO) 11th Annual Meeting in Orlando, FL. Data from this 22 patient trial showed that 0.5 ug/mL of CINTREDEKIN BESUDOTOX delivered via Convection-Enhanced Delivery followed by external beam radiation therapy with or without concurrent temozolomide following tumor resection appears to be safe and well-tolerated in patients with newly diagnosed malignant glioma.
The Phase 1 trial, which was conducted in six U.S. cancer centers, enrolled patients into four cohorts receiving either 0.25 ug/mL or 0.50 ug/mL CINTREDEKIN BESUDOTOX, with either EBRT alone or EBRT plus temozolomide. The last patient was enrolled in the study approximately 20 weeks ago with patients surviving as long as 113 weeks to date. Patients will continue to be monitored for long-term survival.
Related Categories
FDAStocks Mentioned
+0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
